Hemex AG, a European Contract Research Organization (CRO), has significantly broadened its global presence through a newly formed clinical network alliance. The alliance brings together several international partners, combining expertise in oncology, regulatory affairs, digital health, and site management. This collaboration aims to provide comprehensive, end-to-end CRO services to pharmaceutical, biotech, and medtech companies worldwide.
Hemex’s Chief Executive Officer, Franziska Stemmler, explained that this alliance combines the company’s agility with the vision and resources of leading global partners. The goal is to accelerate and improve clinical development, ultimately benefiting patients globally.
The alliance provides clients with streamlined access to global trial networks and diverse patient populations across the United States, Europe, and India. This expanded reach should allow for quicker patient recruitment, improved regulatory compliance, and more efficient cross-border trial execution.
Ajay Nyamati, Co-founder and CEO of Kitsa USA, highlighted the significance of the alliance for Kitsa‘s ecosystem. The partnership integrates Kitsa‘s AI-driven platform with the established expertise of leading CROs. This combination is designed to redefine how clinical trials are planned and conducted, creating what they call “Service-as-Software” offerings.
Dilip Chaudhary, Director of Shankus Hospitals in India, noted the opportunity for the hospital network to leverage its oncology expertise beyond its local patient base. The alliance allows Shankus Hospitals to contribute to larger global trials, accelerating cancer research and its impact.
The combined network boasts over 130 experienced professionals and a robust Quality Assurance (QA) team. This team has a proven track record of successful regulatory inspections by major global authorities, including the FDA, EMA, MHRA, ANVISA, WHO, Health Canada, and TGA.
Andreas Schulz, Founder and Managing Director of the alliance, emphasized that this is more than a simple collaboration; it’s a strategic positioning to meet the evolving needs of global sponsors while advancing healthcare. He believes that the combined strengths of the partners deliver the necessary scale, compliance, and agility to address the increasing complexity of clinical development. The alliance includes other partners like COD Research and Shankus Enem, both based in India, further strengthening its capabilities in site management, regulatory compliance, and BA/BE studies.
Related
